Inhibrx Biosciences, Inc. INBX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on assets | -61%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 6.5×+1.3× | 3.9×— | 4.5×— | 5×— | 5.1×— | |
| Quick ratio | 6.5×+1.3× | 3.9×— | 4.5×— | 5×— | 5.1×— | |
| Cash ratio | 6.1×+1.1× | 3.7×— | 4.3×— | 4.8×— | 5×— | |
| Leverage | ||||||
| Debt-to-assets | 1×+0.5× | 0.7×— | 0.6×— | 0.5×— | 0.4×— | |
| Interest coverage | -9.5×+27.9× | -11.1×+13.5× | -17.1×-0.1× | -28.6×— | -37.3×— | |
| Per Share | ||||||
| Book value per share | -$1.35-122% | $0.52-94.2% | $2.38-79.4% | $4.43-70.1% | $6.11+620% | |
| Valuation | ||||||
| Market capitalization | $1.4B+546% | $1.15B+415% | $487.87M+115% | $213.66M+4.2% | $202.52M-60.0% | |
| Enterprise value | $1.42B+1,233% | $1.13B— | $441.69M— | $133.89M— | $92.53M— | |
| Free cash flow yield | -9.5%+68.6pp | -11.3%— | -29.4%— | -65.6%— | -83.3%— | |
| Earnings yield | -9.3%-829pp | -12.2%-791pp | -22%-746pp | -54.2%— | 874.4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Inhibrx Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Inhibrx Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
